FIELD: medicine.
SUBSTANCE: present group of inventions refers to oncology, and concerns treating tyrosine kinase mediated diseases, selected from a group consisting of ALK, ROS1, TRKA, TRKB, TRKC, JAK2, SRC FAK, ARK5 and combinations thereof. To this end, an effective amount of (7S,13R)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxetriazacyclotridecine-4(5H)-one.
EFFECT: it provides effective treatment of oncological diseases due to ability of this compound to inhibit multiple receptor and non-receptor tyrosine kinases.
45 cl, 21 ex, 4 tbl, 26 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | 2016 |
|
RU2732405C2 |
| COMBINATION THERAPY USING DIARYL MACROCYCLIC COMPOUNDS | 2018 |
|
RU2784853C2 |
| SUBSTITUTED AROMATIC DERIVATIVE WITH CONDENSED RINGS AND COMPOSITION INCLUDING IT AND THEIR USE | 2020 |
|
RU2811484C1 |
| COMPOSITIONS BASED ON SHP2 INHIBITOR AND METHODS OF CANCER TREATMENT | 2018 |
|
RU2805355C2 |
| COMPOSITIONS FOR TREATING CANCER USING ANTAGONISTS WHICH BIND TO THE PD-1 SIGNALING PATHWAY COMPONENT AND MEK INHIBITORS | 2015 |
|
RU2733735C2 |
| DI(ARYLAMINO)ARYL COMPOUNDS | 2008 |
|
RU2463299C2 |
| POINT MUTATIONS IN TRK INHIBITOR-RESISTANT MALIGNANT TUMORS AND RELATED METHODS | 2016 |
|
RU2744852C2 |
| NEW CHEMICAL COMPOUNDS (VERSIONS) AND USING THEM FOR TREATING ONCOLOGICAL DISEASES | 2013 |
|
RU2550346C2 |
| KINASES MODULATION AND INDICATIONS FOR ITS USE | 2012 |
|
RU2631487C2 |
| MACROCYCLIC TYROSINE KINASE INHIBITOR AND ITS USE | 2019 |
|
RU2798231C2 |
